Bavarian Nordic A/S (Bavarian Nordic A/S) FCF Margin % : 13.95% (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Bavarian Nordic A/S FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Bavarian Nordic A/S's Free Cash Flow for the three months ended in Dec. 2023 was $50 Mil. Bavarian Nordic A/S's Revenue for the three months ended in Dec. 2023 was $358 Mil. Therefore, Bavarian Nordic A/S's FCF Margin % for the quarter that ended in Dec. 2023 was 13.95%.

As of today, Bavarian Nordic A/S's current FCF Yield % is 1.30%.

The historical rank and industry rank for Bavarian Nordic A/S's FCF Margin % or its related term are showing as below:

BVNRY' s FCF Margin % Range Over the Past 10 Years
Min: -444.83 Med: -2.64 Max: 19.13
Current: 2.08

During the past 13 years, the highest FCF Margin % of Bavarian Nordic A/S was 19.13%. The lowest was -444.83%. And the median was -2.64%.

BVNRY's FCF Margin % is ranked better than
80.91% of 1032 companies
in the Biotechnology industry
Industry Median: -148.935 vs BVNRY: 2.08

Bavarian Nordic A/S FCF Margin % Historical Data

The historical data trend for Bavarian Nordic A/S's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bavarian Nordic A/S FCF Margin % Chart

Bavarian Nordic A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-444.83

-7.28

-74.66

-36.86

2.01

Bavarian Nordic A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-45.69	-36.54	6.30	9.65	13.95

Competitive Comparison of Bavarian Nordic A/S's FCF Margin %

For the Biotechnology subindustry, Bavarian Nordic A/S's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bavarian Nordic A/S's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bavarian Nordic A/S's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Bavarian Nordic A/S's FCF Margin % falls into.

Bavarian Nordic A/S FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Bavarian Nordic A/S's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	20.747	/	1033.291
	=	2.01 %

Bavarian Nordic A/S's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	49.936	/	358.059
	=	13.95 %

Bavarian Nordic A/S FCF Margin % Related Terms

Thank you for viewing the detailed overview of Bavarian Nordic A/S's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Bavarian Nordic A/S (Bavarian Nordic A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bavarian Nordic A/S (OTCPK:BVNRY) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

BVNKF:USA BAVAc:UK 0DPB:UK BAVA:Denmark BV3:Germany

Address

Philip Heymans Alle 3, Hellerup, DNK, DK-2900

Website

https://www.bavarian-nordic.com

Bavarian Nordic A/S is a biotechnology company focused on the development, manufacturing, and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company has a specific focus on diseases for which the unmet medical need is high. Bavarian generates revenue through government research and development and supply contracts, and from its commercial partnerships. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets.